Baird raised the firm’s price target on Medpace (MEDP) to $613 from $491 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP:
- Medpace price target raised to $655 from $575 at Mizuho
- Medpace price target raised to $485 from $425 at Barclays
- Medpace Holdings Reports Strong Q3 2025 Results
- Medpace Holdings Inc. Reports Strong Q3 2025 Growth
- Medpace Holdings: Overvaluation Concerns Amid Growth Projections and Market Positioning